Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1531842
                    [Title] => FDA approves Genentech drug for advanced lung cancer
                    [Summary] => 
The Food and Drug Administration on Friday conditionally approved an experimental Genentech drug for patients with a certain type of lung cancer who have few other options.

                    [DatePublished] => 2015-12-11 16:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 1462169
                    [AuthorName] => Linda A. Johnson
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => http://media.philstar.com/images/the-philippine-star/world/20151212/Lung-X-ray.jpg
                )

            [1] => Array
                (
                    [ArticleID] => 1252258
                    [Title] => FDA approves Roche drug for chronic leukemia based on research that it slows disease
                    [Summary] => 
The Food and Drug Administration on Friday approved a new drug from Roche to help treat patients with a type of cancer of the blood and bone marrow.

                    [DatePublished] => 2013-11-02 05:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => http://img534.imageshack.us/img534/3584/4nve.jpg
                )

            [2] => Array
                (
                    [ArticleID] => 1206021
                    [Title] => FDA panel says Roche drug works for new approach in treating breast cancer ahead of surgery
                    [Summary] => 
Government cancer experts say a Roche drug has shown effectiveness as a new option for treating breast cancer before tumor-removing surgery.

                    [DatePublished] => 2013-09-13 07:10:38
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 1510054
                    [AuthorName] => Matthew Perrone
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => http://imageshack.us/a/img34/3839/hlqx.jpg
                )

            [3] => Array
                (
                    [ArticleID] => 912240
                    [Title] => FDA approves new targeted breast cancer drug
                    [Summary] => 
The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

                    [DatePublished] => 2013-02-23 00:20:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => World
                    [SectionUrl] => world
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 763066
                    [Title] => Avastin disappoints against ovarian cancer
                    [Summary] => 
Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer,  too.
                    [DatePublished] => 2011-12-30 01:07:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => 
                    [SectionUrl] => 
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 756015
                    [Title] => Big promise seen in 2 new breast cancer drugs
                    [Summary] => 
Breast cancer experts are cheering what could be some of the biggest advances in more than a decade: two new medicines that significantly delay the time until women with very advanced cases get worse.
                    [DatePublished] => 2011-12-08 11:17:49
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => 
                    [SectionUrl] => 
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 749485
                    [Title] => FDA revokes approval of Avastin for breast cancer
                    [Summary] => 
The blockbuster drug Avastin should no longer be used in advanced breast cancer patients because there's no proof that it extends their lives and it presents dangerous side effects, the government declared Friday.
                    [DatePublished] => 2011-11-19 02:08:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => 
                    [SectionUrl] => 
                    [URL] => 
                )

            [7] => Array
                (
                    [ArticleID] => 680468
                    [Title] => Cheaper eye drug proves as good as pricier one
                    [Summary] => 
A new study shows that a cheaper drug for a common eye disease is as  effective as a more expensive one approved for the condition.
                    [DatePublished] => 2011-04-29 03:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => 
                    [SectionUrl] => 
                    [URL] => 
                )

            [8] => Array
                (
                    [ArticleID] => 653470
                    [Title] => Early success of Roche drug vs lung cancer cited
                    [Summary] => SWITZERLAND — Roche announced this week that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study has met its primary endpoint.
                    [DatePublished] => 2011-02-03 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [9] => Array
                (
                    [ArticleID] => 509392
                    [Title] => Abbott Laboratories acquires Belgian chemical maker for $6.6 billion
                    [Summary] => 
Abbott Laboratories on Monday said it would pay $6.6 billion for the pharmaceutical business of Belgian chemicals maker Solvay in a move to further expand internationally and add to its product portfolio.
                    [DatePublished] => 2009-09-30 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Business
                    [SectionUrl] => business
                    [URL] => 
                )

        )

)

Genentech

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1531842
                    [Title] => FDA approves Genentech drug for advanced lung cancer
                    [Summary] => 
The Food and Drug Administration on Friday conditionally approved an experimental Genentech drug for patients with a certain type of lung cancer who have few other options.

                    [DatePublished] => 2015-12-11 16:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 1462169
                    [AuthorName] => Linda A. Johnson
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => http://media.philstar.com/images/the-philippine-star/world/20151212/Lung-X-ray.jpg
                )

            [1] => Array
                (
                    [ArticleID] => 1252258
                    [Title] => FDA approves Roche drug for chronic leukemia based on research that it slows disease
                    [Summary] => 
The Food and Drug Administration on Friday approved a new drug from Roche to help treat patients with a type of cancer of the blood and bone marrow.

                    [DatePublished] => 2013-11-02 05:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => http://img534.imageshack.us/img534/3584/4nve.jpg
                )

            [2] => Array
                (
                    [ArticleID] => 1206021
                    [Title] => FDA panel says Roche drug works for new approach in treating breast cancer ahead of surgery
                    [Summary] => 
Government cancer experts say a Roche drug has shown effectiveness as a new option for treating breast cancer before tumor-removing surgery.

                    [DatePublished] => 2013-09-13 07:10:38
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 1510054
                    [AuthorName] => Matthew Perrone
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => http://imageshack.us/a/img34/3839/hlqx.jpg
                )

            [3] => Array
                (
                    [ArticleID] => 912240
                    [Title] => FDA approves new targeted breast cancer drug
                    [Summary] => 
The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

                    [DatePublished] => 2013-02-23 00:20:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => World
                    [SectionUrl] => world
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 763066
                    [Title] => Avastin disappoints against ovarian cancer
                    [Summary] => 
Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer,  too.
                    [DatePublished] => 2011-12-30 01:07:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => 
                    [SectionUrl] => 
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 756015
                    [Title] => Big promise seen in 2 new breast cancer drugs
                    [Summary] => 
Breast cancer experts are cheering what could be some of the biggest advances in more than a decade: two new medicines that significantly delay the time until women with very advanced cases get worse.
                    [DatePublished] => 2011-12-08 11:17:49
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => 
                    [SectionUrl] => 
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 749485
                    [Title] => FDA revokes approval of Avastin for breast cancer
                    [Summary] => 
The blockbuster drug Avastin should no longer be used in advanced breast cancer patients because there's no proof that it extends their lives and it presents dangerous side effects, the government declared Friday.
                    [DatePublished] => 2011-11-19 02:08:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => 
                    [SectionUrl] => 
                    [URL] => 
                )

            [7] => Array
                (
                    [ArticleID] => 680468
                    [Title] => Cheaper eye drug proves as good as pricier one
                    [Summary] => 
A new study shows that a cheaper drug for a common eye disease is as  effective as a more expensive one approved for the condition.
                    [DatePublished] => 2011-04-29 03:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => 
                    [SectionUrl] => 
                    [URL] => 
                )

            [8] => Array
                (
                    [ArticleID] => 653470
                    [Title] => Early success of Roche drug vs lung cancer cited
                    [Summary] => SWITZERLAND — Roche announced this week that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study has met its primary endpoint.
                    [DatePublished] => 2011-02-03 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [9] => Array
                (
                    [ArticleID] => 509392
                    [Title] => Abbott Laboratories acquires Belgian chemical maker for $6.6 billion
                    [Summary] => 
Abbott Laboratories on Monday said it would pay $6.6 billion for the pharmaceutical business of Belgian chemicals maker Solvay in a move to further expand internationally and add to its product portfolio.
                    [DatePublished] => 2009-09-30 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Business
                    [SectionUrl] => business
                    [URL] => 
                )

        )

)

abtest

FDA approves Genentech drug for advanced lung cancer

By Linda A. Johnson | December 11, 2015 - 4:00pm

The Food and Drug Administration on Friday conditionally approved an experimental Genentech drug for patients with a certain...

Health And Family

FDA approves Roche drug for chronic leukemia based on research that it slows disease

November 2, 2013 - 5:00am

The Food and Drug Administration on Friday approved a new drug from Roche to help treat patients with a type of cancer of...

Health And Family

FDA panel says Roche drug works for new approach in treating breast cancer ahead of surgery

By Matthew Perrone | September 13, 2013 - 7:10am

Government cancer experts say a Roche drug has shown effectiveness as a new option for treating breast cancer before tumor-removing...

Health And Family

FDA approves new targeted breast cancer drug

February 23, 2013 - 12:20am

The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

World

Avastin disappoints against ovarian cancer

December 30, 2011 - 1:07am

Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer, too.

Big promise seen in 2 new breast cancer drugs

December 8, 2011 - 11:17am

Breast cancer experts are cheering what could be some of the biggest advances in more than a decade: two new medicines that significantly delay the time until women with very advanced cases get worse.

FDA revokes approval of Avastin for breast cancer

November 19, 2011 - 2:08am

The blockbuster drug Avastin should no longer be used in advanced breast cancer patients because there's no proof that it extends their lives and it presents dangerous side effects, the government declared Frid...

Cheaper eye drug proves as good as pricier one

April 29, 2011 - 3:00am

A new study shows that a cheaper drug for a common eye disease is as effective as a more expensive one approved for the condition.

Early success of Roche drug vs lung cancer cited

February 3, 2011 - 12:00am

SWITZERLAND — Roche announced this week that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study has met its primary endpoint.

Science and Environment

Abbott Laboratories acquires Belgian chemical maker for $6.6 billion

September 30, 2009 - 12:00am

Abbott Laboratories on Monday said it would pay $6.6 billion for the pharmaceutical business of Belgian chemicals maker Solvay in a move to further expand internationally and add to its product portfolio.

Business